Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2005

View Archived Issues

UCB profiles recent pipeline developments

NG2-73 enters phase II for insomnia

Roche and Maxygen to codevelop recombinant factor VIIa products

Zadaxin and pegylated interferon alpha fail to demonstrate statistically significant benefit in HCV

ActivBiotics and Metaphore sign merger agreement

Amgen to acquire Abgenix

Anadys selects ANA-773 as drug development candidate for cancer

Plavix recommended for use in new PAD guidelines

FDA Advisory Committee vote positively on Rotateq

Phase I/II study investigates CB-7630 for advanced prostate cancer

European CHMP to issue updated positive opinion for Macugen

Alnylam and sanofi pasteur update status of avian flu projects

Protox submits IND for phase I trials of PRX-302

Maximum tolerated dose determined for Anyara

MN-001 significantly improves measures of respiratory function in asthma patients

Preclinical and clinical antitumor activity of atiprimod reported

Bendamustine effective against refractory or relapsed non-Hodgkin's lymphoma and multiple myeloma

Clinical efficacy of forodesine for refractory/relapsed cutaneous T-cell lymphoma and leukemia

Motexafin gadolinium improves survival of mice with ALS

Preclinical profile of SCA-136 disclosed by Wyeth

Antalarmin lacks efficacy in primate models of cocaine self-administration and discrimination

CB2 receptor agonist slows ALS progression in mice

Spotlight on rufinamide from American epilepsy meeting

Tamiflu gains positive European and Swiss opinions for child flu prevention

Depakote ER receives new approval in bipolar disorder

Initiation of rolling NDA for satraplatin in hormone-refractory prostate cancer

Pharmasset present data on their new anti-HCV agent

Recent patents report new therapeutic agents for metabolic disorders

Novel agents with potential for treatment of pain described